Abstract:Abstract Background Randomized clinical trials of Alzheimer’s‐modifying drugs typically report a clinical effect as the final observation difference in means for a cognitive endpoint between treated and placebo groups. However, randomization of subjects naturally following different cognitive decline trajectories could produce a between‐group endpoint difference even when a drug has no disease‐modifying effect. Recent work used data from ADNI subjects matching trial inclusion criteria to simulate patient trajectories [Jutten et al. (2021). https://doi.org/10.1212/WNL.0000000000012022 ]. We build on such simulations by incorporating a trial’s specific design parameters, including multiple visits, visit time windowing, dropout rate, and measurement noise using jittering. We estimate treatment‐independent group differences in a cognitive endpoint’s rate of change in simulations of the Phase 3 aducanumab and lecanemab trials. Method 563 ADNI subjects matched inclusion criteria for the identically designed Phase 3 aducanumab trials EMERGE and ENGAGE [clinicaltrials.gov/ct2/show/NCT02484547]. We fitted a continuous time linear mixed effect model tracking CDSRB change from baseline (CDRSBΔbl). ADNI subjects’ baseline data were resampled and jittered, generating data for 1,070 synthetic subjects total while preserving the real trials’ baseline Alzheimer’s stage distribution. Subjects were randomized 1:1 to “treated” and “placebo” groups, but without any treatment effect. We simulated 4 visits, ∼26 weeks apart, with 30% dropout. Our sample size and visit scheme matches the real trials’ Statistical Analysis Plans. We generated 10,000 simulated trials, each a unique randomization of subject trajectories. The “treated” vs. “placebo” CDRSBΔbl linear slope difference was extracted from each simulation. We repeated this procedure for the demographics and design of lecanemab’s Phase 3 trial Clarity AD [clinicaltrials.gov/ct2/show/NCT03887455]. Result Histograms of simulated slope differences differ between the trial designs (see Figures). Averages are zero because there is no simulated treatment effect. Each successful trial’s real‐world difference (EMERGE high dose: –22%, Clarity AD: –27%) corresponds to a statistically significant reduction in cognitive decline rate for treated subjects vs. placebo. Conclusion Our results suggest low false positive probabilities for the successful trials. Cohort composition, sampling, and other trial characteristics might influence treatment‐independent group difference in cognitive decline rate. With our method, future trials could target treatment effects outside the target population’s false positive range.

Unlocking Cognitive Analysis Potential in Alzheimer's Disease Clinical Trials: Investigating Hierarchical Linear Models for Analyzing Novel Measurement Burst Design Data

Modeling of Correlated Cognitive Function and Functional Disability Outcomes with Bounded and Missing Data in a Longitudinal Aging Study

Natural cubic splines for the analysis of Alzheimer's clinical trials

Post-Hoc Assessment of Cognitive Efficacy in Alzheimer's Disease Using a Latent Growth Mixture Model in AMBAR, a Phase 2B Randomized Controlled Trial

Combining Multiple Markers to Improve the Longitudinal Rate of Progression-Application to Clinical Trials on the Early Stage of Alzheimer's Disease.

Probabilistic Clustering using Shared Latent Variable Model for Assessing Alzheimers Disease Biomarkers

Cognitive Biomarker Prioritization in Alzheimer's Disease using Brain Morphometric Data

BAyesian Bent-Line Regression model for longitudinal data with an application to the study of cognitive performance trajectories in Wisconsin Registry for Alzheimer's Prevention

Analytic Challenges in Clinical Trials in Early Alzheimers Disease

A COMPUTATIONAL MONTE CARLO SIMULATION STRATEGY TO COMPARE THE ONSET OF DIFFERENT BIOMARKER AND COGNITIVE CHANGES

A Computational Monte Carlo Simulation Strategy to Determine the Temporal Ordering of Abnormal Age Onset Among Biomarkers of Alzheimer's Disease

The relative efficiency of time-to-progression and continuous measures of cognition in pre-symptomatic Alzheimer's

Joint Modeling of Transitional Patterns of Alzheimer'S Disease

Simulation‐based effect size analysis in the absence of drug effects to inform the design of clinical trials in Alzheimer’s disease

A joint model for multiple dynamic processes and clinical endpoints: application to Alzheimer's disease

Cognitive biomarker prioritization in Alzheimer’s Disease using brain morphometric data

Joint Modeling of Biomarker Cascades Along An Unobserved Disease Progression with Differentiate Covariate Effects: An Application in Alzheimer's Disease

Comprehensive Methodology for Sample Augmentation in EEG Biomarker Studies for Alzheimers Risk Classification

Individualized and Biomarker-Based Prognosis of Longitudinal Cognitive Decline in Early Symptomatic Alzheimer's Disease

Variational Bayesian partially linear mean shift models for high-dimensional Alzheimer's disease neuroimaging data

Predicting Time-to-conversion for Dementia of Alzheimer's Type using Multi-modal Deep Survival Analysis